Grünenthal Group: Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy

Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from ...
Pressat

Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy

Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the ...